期刊文献+

培美曲塞应用于肺癌患者化疗中的效果及对细胞免疫功能的影响

下载PDF
导出
摘要 目的:探讨培美曲塞应用于肺癌患者化疗中的效果及对细胞免疫功能的影响。方法:选择我院2015年12月至2016年12月收入的肺癌患者86例,分为A组和B组,每组各43例,给予A组患者培美曲塞联合顺铂化疗,给予B组长春瑞滨联合顺铂化疗,观察两组临床治疗效果以及细胞免疫功能变化。结果:A组患者临床治疗总有效例率为23(53.5%),显著高于B组的14(32.6%)(P<0.05);A组治疗后NK细胞百分比和CD4/CD8比例均显著高于B组(P<0.05),CD3、CD4、CD8细胞百分比显著低于对照组(P<0.05)。结论:培美曲塞在肺癌患者化疗中,能够有效增强临床治疗效果,提高免疫功能,避免或者改善医院感染事件,大大值得临床推广。
作者 邢红雨
机构地区 解放军
出处 《中外女性健康研究》 2017年第9期39-40,共2页 Women's Health Research
  • 相关文献

参考文献5

二级参考文献42

  • 1Yang CH, Simms L, Park K, etal. Efficacy and safety of cispl- atin/pemetrexed versus cisplatin/gemcitabine as first-line treat- ment in East Asian patients with advanced non-normal cell lung cancer: results of an exploratory subgroup analysis of a phaseⅢ trial [J]. J Thorac Oncol, 2010, 5(5) :688-695.
  • 2FERLAY J, SHIN H R, BRAY F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 [ J ] . Int J Cancer, 2010, 127: 2893-2917.
  • 3AZZOLI C G, BARKER S J R, TEMIN S, et al. American Society of Clinical Oncology Clinical Practice guideline update on chemotherapy for stage IV non-small-cell lung cancer [ J ] . J Clin Oncol, 2009, 27: 6251-5266.
  • 4ZINNER R G, FOSSELLA F V, GLADISH G W, et al. Phase 1T study of pemetrexed in combination with carboplatin in the first-line treatment of advanced non-small cell lung cancer [ J ] . Cancer, 2005, 104: 2449-2456.
  • 5JONES R J, TWELVES C J. Pemetrexed: a muhitargeted antifolate (ALIMTA), LY-231514) [ J ] . Expert Rev Anticancer Ther, 2002, 2(1): 13-22.
  • 6DELBALDO C, MICHIELS S, SYZ N, et al. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis [ J ] . JAMA, 2004, 292: 470-484.
  • 7HANNA N, SHEPHERD F A, FOSSELLA F V, et al. Randomized phase llI trim of pemetrxed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy [ J ] . J Clin Oncol, 2004, 22(9): 1589- 1597.
  • 8SCAGLIOTTI G V, PARIKH P, VOL PAWEL J, et al. Phase m study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced stage non-small cell lung cancer [ J ] . J Clin Oncal, 2008, 26(21): 3543-3551.
  • 9SCAGLIOTTI G V, PARK K, PATIL S, et al. Survival without toxicity for cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemonaive patients with advanced non-small cell lung cancer: a risk-benefit analysis of a large phase 111 study [ J ] . Euro J Cancer, 2009, 13: 2298-2303.
  • 10Satoh H, Ishikawa H, Kurishima K, et al. Cut-off levels of NSE to differentiate SCLC from NSCLC[ J]. OncolRep,2012,9(3):581 -583.

共引文献52

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部